Event Details
Date Unknown
Description
Celgene used the REMS (Risk Evaluation and Mitigation System) program to restrict access to its drugs Revlimid and Thalomid, delaying generic competition.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Celgene | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_028420.jpg
The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.
Related Events
Events with shared participants
The F.D.A. approved Celgene's application to treat erythema nodosum leprosum, a complication of leprosy, with its drug Thalomid (thalidomide).
1998-01-01 • United States
Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid.
1999-01-01 • New Jersey
Celgene reported that only 100 prescriptions a year were being written for Thalomid to treat the approved skin condition.
2007-01-01 • United States
Celgene's application was approved by the F.D.A. to treat erythema nodosum leprosum, a complication of leprosy.
1998-01-01 • United States
Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalomid.
1999-06-01 • New Jersey
Celgene reported that only about 100 prescriptions per year were written for the approved skin condition (leprosy complication).
2007-01-01 • United States
Celgene reported that 92 percent of Thalomid's prescriptions were being written to treat cancer, despite lack of formal approval for those uses.
2001-01-01
Celgene received formal approval to market Thalomid and Revlimid for certain cancers.
2005-01-01
Revlimid was introduced to the market at an initial cost of about $6,000 per month.
2006-01-01
Celgene settled a lawsuit regarding illegal marketing to avoid protracted litigation.
2017-01-01
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event